Recommended

New Webinar: Neurological disorders – organoids for early drug discovery
Listen to our latest podcast: breaking resistance – the future of immunotherapy in oncology
Download now: The latest advancements and breakthroughs in immuno-oncology
Register now: Ion Channel Drug Discovery – Recent Advances in Novel Non-Opioid Pain Research
Register now: SAFIRE: AI predicted ADME for drug discovery: leveraging bioprint
Report

Beyond the lab: artificial intelligence

Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.

Dear readers,

Download this report to discover the transformative potential of artificial intelligence (AI) in drug discovery, highlighting recent advancements such as the development of a highly accurate drug target interaction model at the University of Central Florida. Experts discuss the application of AI in streamlining drug screening processes and accelerating the identification of potential treatments, particularly in response to urgent needs like the COVID-19 pandemic.

Expert insights from:

  • Dr Ozlem Ozmen Garibay and team, University of Central Florida
  • Aaron C. Daugherty, Vice President, Aria Pharmaceuticals
  • Dr Hari Shroff, Janelia Research Campus
  • Dr Mark Eller, Senior Vice President of Research and Development at Aria Pharmaceuticals.
  • Dr Espen Basmo Ellingsen, University of Oslo 
  • Dr Alex Zhavoronkov, CEO of Insilico Medicine

Download now to read more about:

  • Game-changing pan-TEAD inhibitor for solid tumours
  • Documenting the mammalian brain using machine learning
  • Improving ovarian cancer outcomes with AI
  • AI system develops features of complex brains.

Experts caution against overinflated expectations regarding AI’s capabilities, emphasising the need for a balanced understanding of its role as a supportive tool in pharmaceutical research. The report highlights ongoing advancements in AI-driven drug discovery while acknowledging the importance of realistic expectations and continued investment in this evolving field.

We are committed to providing you with the highest quality content, and we believe that this report will deliver a different perspective on the topics covered.

Thank you for your continued support.

Sincerely,

Taylor Mixides

Editor

Drug Target Review

Interested? Please register your details in the box to receive this exclusive content.